SGCB and chronic obstructive pulmonary disease: These observations provide insight into the potential therapeutic benefits of drugs targeting NO-sGC-cGMP and point to the unmet need for a large randomized controlled trial to explore further the efficacy of using therapies, particularly inhaled therapies targeting NO-sGC-cGMP pathway for the management of PH due to COPD.